

Soft Matter

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Thermodynamics of Cell-Penetrating HIV1 TAT Peptide Insertion into PC/PS/CHOL Model Bilayers through Transmembrane Pore: the Roles of Cholesterol and Anionic Lipid

Yuan Hu^a and Sandeep Patel^{*b}

Received Xth XXXXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXXXX 20XX

First published on the web Xth XXXXXXXXXXXX 200X

DOI: 10.1039/b000000x

Efficient delivery of pharmaceutically active molecules across cellular membranes using cell penetrating peptides (CPPs), such as the cationic human immunodeficiency virus-1 trans-acting activator of transcription peptide (HIV-1 TAT), continues to attract scientific attention in drug design and disease treatment. Experimental results show that the TAT peptide is not only capable of directly penetrating the biological membrane in a passive manner, but also forming physical, membrane-spanning pores that may facilitate transport. Experiments further show that anionic lipids accelerate peptide permeation within a range of mole percentage composition. In this work, we explored the structures and translocation thermodynamics of the cationic TAT peptide across a series of DPPC/DPPS model membranes with the presence of 0-30 mol % cholesterol. We computed the potentials of mean force by using umbrella sampling molecular dynamics simulations coupled to Martini coarse-grained force field. We systematically investigated the roles of cholesterol and anionic lipid (membrane surface charge) in TAT peptide translocation. In qualitative agreement with experimental findings, the barrier heights were significantly reduced in the presence of anionic lipids. A toroidal hydrophilic pore was strongly suggested by membrane structure analysis. Cholesterol stabilizes the liquid-ordered (Lo) phase of membranes and increases the elastic stiffness of bilayer. Consequently, it hinders transmembrane pore formation and thus modulates solute permeability, since the liquid-ordered phase suppresses reorientation of the lipid molecules on simulation time scales. Though cholesterol contributes marginally to the total free energy associated with peptide permeation, the coordination of cholesterol to the peptide weakens more favorable peptide-lipid interactions. Addition of the anionic lipid DPPS to the neutral DPPC bilayer leads to emergence and further enhancement of an interfacially stable state of the peptide due to the favorable peptide-anionic lipid interactions. Translocation free energy barriers decrease in lockstep with increasing DPPS composition in the model bilayers simulated. Finally, we investigated the size of hydrophilic pores emerging in our simulations, as well as qualitative mobility of the peptide on the membrane surface.

1 . See DOI: 10.1039/b000000x/

2 1 Introduction

3 HIV-1 TAT, the first protein transduction domain
4 (PTD)^{1,2} discovered in 1988, also known as a cell-
5 penetrating peptide (CPP), has been constantly gar-
6 nering significant attention in drug-delivery for nearly
7 three decades. Experiments have shown that CPPs in-
8 cluding the TAT peptide can traverse cell membranes
9 alone or with molecular cargos of poor cellular perme-
10 ability, such as semiconductor quantum dots (QDs)^{3,4},
11 DNA⁵, RNA⁶, vaccines⁷, protein/peptide based phar-
12 maceutics⁸, nanoparticles⁹, and even liposomes¹⁰. A
13 wide arsenal of state-of-the-art techniques have been
14 used to attack questions surrounding the binding and

† Electronic Supplementary Information (ESI) available: [The charge density and mass density profiles of the membrane systems, bond order parameter of the membrane in equilibrated condition, PMF contributions from water and cholesterol are included in the supplementary information.]

^a Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. ^b Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, USA. Fax: 302-831-6335; Tel: 302-831-6024; E-mail: sapatel@udel.edu

cellular internalization mechanisms, including labeled and label-free methods such as isothermal titration calorimetry (ITC)¹¹, single-molecule fluorescence microscopy¹², solid-state NMR (SSNMR)¹³, time-of-flight mass spectrometry (MALDI-TOF MS)^{14,15}, lamellar neutron diffraction¹⁶, second harmonic generation (SHG)¹⁷, and so on. However, to the best of our knowledge, there is still a lack of understanding about the origins, selectivity, and structural and thermodynamic determinants of the cell-penetrating ability of these peptides.

Recent experimental studies^{12,16,18} of live cells, cellular constructs, model membrane/lipid bilayers, and the like, frequently suggest pore-like membrane configurations as possible means for CPPs translocating across bilayer along with effects of ions and water flux. Kubitschek *et al.*¹² systematically examined the permeation of a fluorophore labeled TAT peptide across the model giant unilamellar vesicles (GUVs) by using high-speed single-particle tracking (SPT) and confocal laser scanning microscopy (CLSM). The authors discovered no TAT peptide translocation in pure phosphatidylcholine (PC) and cholesterol (CHOL) only GUVs, even at high concentrations. However, they showed that systematically increasing the phosphatidylserine (PS) content in PC lipid bilayers dramatically increased the permeability of the TAT peptide. The TAT peptide was able to rapidly translocate into PC, PS and cholesterol mixed GUV with a critical threshold of 40 mol % anionic PS component. Peptides directly translocated into GUVs in a passive manner. The efflux experiments of tracer molecules suggested that TAT peptide translocation may be associated with formation of an intramembrane pore estimated to be 1.3 nm ~ 2.0 nm.

Acknowledging the work of Kubitschek *et al.*¹² on the clean vesicle systems, we used molecular dynamics simulations (MD) to understand the selectivity of TAT translocation across PC/PS/CHOL systems from the perspective of structural and thermodynamic features at the microscopic level. We constructed several model lipid systems to interrogate the role of cholesterol and anionic lipid components in a systematic manner. First we compared the dependence of cholesterol in pure PC or PS systems with 0-30 mol % cholesterol. Then, we investigated the correlation of anionic PS lipids with the TAT peptide translocation into DPPC/DPPS mixed lipid bilayers with 0 or 20 mol % cholesterol, which were used to reproduce the membrane compositions studied by Kubitschek *et al.*¹². Specifically, we used the umbrella sampling (US) method utilizing the most widely applied MARTINI coarse-grained (CG) force field to estimate the free energetics for transferring the cationic TAT peptides from bulk aqueous-like environment to the hydrophobic

center of the bilayer. We discuss the results in two parts: 1) the effect of cholesterol composition, 2) the role of anionic lipid component in TAT translocation into model lipid bilayers. The results of the potentials of mean force (PMFs), effect of different conformations, and PMF contributions from the system components have also been discussed in each section. We aim to recapitulate the experimental observation with CG models. At the very least, we seek to explore the qualitative trend in free energetics and further obtain molecular level insight into CPP translocation.

2 Methods

The Martini Coarse-grained (CG) model has been successfully used to study soft matter and membrane biophysics, such as lipid/surfactant self-assembly, vesicle formation and fusion, peptide-membrane binding, nano-particles and short peptides translocation, and so on¹⁹⁻²². The force field maps four consecutive heavy atoms of a molecule at an atomic resolution to one bead, except for ring-like structures. It considers four main types of interaction sites such as polar (P), nonpolar (N), apolar (C), and charged (Q). Moreover, within a main type, subtypes are used to distinguish the hydrogen-bonding capabilities (d = donor, a = acceptor, da = both, 0 = none) or the degree of polarity (from 1 = low polarity to 5 = high polarity). Since the diffusive motion for water in CG model is the same as in all-atom (AA) models but that four water molecules are mapped to one CG water, the effective simulation time in the CG model is generally rationalized to be approximately four times as large as that in AA model²³. Although the resolution is reduced in Martini model due to neglecting atomic details, the CG force field is still sufficient to reproduce and predict structural and free energetic behaviors^{24,25}. The Martini force field with Particle Mesh Ewald (PME) is shown to provide a more realistic description of the interaction of charged molecules with lipid membranes and is also found necessary to induce and accommodate transmembrane pores during solute translocation, although the use of PME is not the standard method^{26,27}.

In this work, we used the latest non-polarizable Martini coarse-grained (CG) model developed by Marrink *et al.*^{23,28,29} to simulate interactions among system components, such as peptides, lipids, cholesterol, water and ions. We used the TAT protein transduction domain (PTD) fragment corresponding to amino acids 48 to 57 of the domain of HIV-1 TAT protein (Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg, +8 charges). The N-terminus and the C-terminus of the TAT peptide were considered as neutral, and all the backbones were represented by P5

beads as widely used in this CG model^{19,20,30–32}. 1,2-¹⁴³
 dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-¹⁴⁴
 dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS) lipids¹⁴⁵
 and cholesterol were used as the building blocks of the¹⁴⁶
 model bilayers. In Martini, the DPPC lipid is made of
 four head group beads and eight tail beads. The DPPS
 lipid structure and parameters are the same as the DPPC
 lipid except that the head group choline changes from
 positively charged (type Q0) to neutral bead (type P5) to
 represent serine²¹. Fig. 1 illustrates the CG structures of
 HIV-1 TAT peptide, water, ions, cholesterol, DPPC and
 DPPS lipids used in the framework of the Martini force
 field and the simulation system cells.




Fig. 1 Structures of Coarse-Grained (CG) cholesterol,¹⁵⁵
 DPPC, DPPS, and mixed bilayer, water, ions, and TAT, and¹⁵⁶
 a typical lipid mixture system.¹⁵⁷

2.1 Simulation Protocol¹⁵⁸

All the MD simulations were carried out using MPI sup-¹⁶²
 ported GROMACS software package (version 4.6.3), sin-¹⁶³
 gle precision. The simulation cell consists of a rectan-¹⁶⁴
 gular box. We constructed 14 systems including DPPC¹⁶⁵
 or DPPS only systems with 0-30 mol % cholesterol, and¹⁶⁶
 0-100 mol % DPPS systems with 0-20 mol % cholesterol.¹⁶⁷
 The system compositions are summarized in Table 1.¹⁶⁸
 Each cholesterol-free system, such as the DPPC only sys-¹⁶⁹
 tem, contains 1 TAT peptide, 256 lipid molecules (128¹⁷⁰
 lipids per leaflet), surrounded by 7554 water and 150mM¹⁷¹
 NaCl ions (82 sodium and 82 chloride ions). The systems¹⁷²
 containing cholesterol and/or DPPC/DPPS mixture were¹⁷³

constructed by substituting DPPC to DPPS and chole-
 sterol equally from both leaflets. Water molecules were
 replaced to counter-ions when necessary to keep the sys-
 tem charge neutral.

Table 1 Composition of systems modelled. Each system in-
 cludes one TAT peptide (+8 charges), which is not shown in
 the table.

Ratio ^a	CHOL	DPPC	DPPS	Water	Na ⁺	Cl ⁻
0: 100: 0	0	256	0	7554	82	90
10: 90: 0	26	230	0	7544	82	90
20: 80: 0	52	204	0	7554	82	90
30: 70: 0	76	180	0	7554	82	90
0: 75: 25	0	64	192	7362	274	90
0: 50: 50	0	128	128	7426	210	90
0: 25: 75	0	192	64	7490	146	90
20: 60: 20	52	152	52	7502	134	90
20: 40: 40	52	102	102	7452	184	90
20: 20: 60	52	52	152	7402	234	90
30: 0: 70	76	0	180	7374	262	90
20: 0: 80	52	0	204	7350	286	90
10: 0: 90	26	0	230	7314	312	90
0: 0: 100	0	0	256	7298	338	90

^a: Ratio of CHOL:DPPC:DPPS

We first minimized each lipid system with the steep-
 est descent method and then equilibrated it under con-
 stant particle, pressure and temperature (NPT) ensemble
 molecular dynamics simulations for 1 μ s at 1 atm. Since
 the phase transition temperatures of DPPC and DPPS
 are 314 K and 326 K, respectively, we carried out all
 the simulations at 350 K. This temperature setting is
 also carefully tested and suggested by the all atom sim-
 ulations Cascales' et al³³. We used a time step of 20
 fs and updated the neighbor list every 10 steps. The
 Lennard-Jones (LJ) and electrostatic (Coulomb) interac-
 tions were calculated by using simple spherical cutoff at
 a distance of 1.2 nm with a smooth switching function
 of distances 0.9 nm and 0.0 nm, respectively. The condi-
 tionally convergent long range electrostatic interactions
 were modeled by using the PME method with a fourth-
 order spline and a 0.12 nm grid spacing. The relative
 dielectric constants were set to 15 for use in combination
 with the non-polarizable water force fields. To maintain
 the temperature at 350 K, we used the velocity rescaling
 scheme with time constants of 1.0 ps. We used two tem-
 perature coupling groups: water and ions were considered
 as one, and the remaining atoms were set as the second
 group. We used the Parrinello-Rahman coupling scheme
 with 12.0 ps to maintain the pressure of 1 atm for the
 systems. To keep the bilayer in a tensionless state, peri-
 odic boundary conditions with a semi-isotropic pressure

coupling algorithm with a 3.0×10^{-4} bar $^{-1}$ compressibility was used. The LINCS algorithm³⁴ was used to apply the bond constraint present in Martini force fields.

2.2 Umbrella Sampling Simulations

To obtain a PMF for the transfer of TAT in each system, we used 61 umbrella sampling (US) windows ranging from 0.0 to 6.0 nm at a spacing of 0.1 nm along our chosen reaction coordinate (Rxn. Coord.) ξ , which is the z-dimension distance between the center of mass (c.o.m.) of peptide and c.o.m of the membrane (here the whole membrane including DPPC, DPPS, and CHOL). We first generated initial configurations in the windows along the specified Rxn. Coord. by growing a TAT peptide in the center of the above equilibrated systems, and further equilibrated the peptide-bilayer-water-ion system for about 200 ns. In order to prevent the unnecessary drift of the membrane in the direction of the membrane normal, we applied a position restraint, along the z-dimension, with a force constant of 1000 kJ/mol/nm² on the charged groups (NC3, PO4) of lipid molecules during the peptide growing-in phase in all simulations. In this work, the membrane interface is defined as the intersection region of the headgroup and solution mass density profiles (the mass density profiles are shown in Fig. S2 in SI). The interface is estimated at 2.0 nm from the center of the bilayer in all systems. The membrane thickness is approximately 4.0 nm. For US MD simulations, we applied harmonic potentials with a force constant of 1500 kJ/mol/nm² to restrain the peptide at each window. Each window was simulated for 600 ns, and the total simulation time period was 36.6 μ s. The details of the window setup and US method have been described in our recent work¹⁹.

The weighted histogram analysis method (WHAM) was used for post-simulation unbiasing of umbrella sampling data³⁵. We used the Gromacs tool 'g_wham' to generate the final PMF. The Visual Molecular Dynamics (VMD) package³⁶ was used to monitor the simulation, visualization and graphics preparation for this work.

2.3 System Component Contributions in Potentials of Mean Force

The contribution to the total PMF from the system component, α , (i.e α = water molecules, α = lipids, α = ions, α = cholesterol) is:

$$W_{\alpha}(\eta) = - \int_{\eta_0}^{\eta_1} d\eta \langle F_{z,peptide-com}^{\alpha} \rangle_{\eta} \quad (1)$$

where η_0, η_1 is the value of the Rxn. Coord. in the reference state, η is the dummy variable of integration, $\langle F_{z,peptide-com}^{\alpha} \rangle_{\eta}$ is the average z-component of the total force on the peptide center of mass arising from interactions with system component α . The total PMF is a sum over the system component contributions:

$$W(\eta) = \sum_{\alpha} W_{\alpha}(\eta) \quad (2)$$

The instantaneous force on the peptide from system component α , $F_{z,peptide-com}^{\alpha}$, was computed post-simulation by processing the trajectories of each US window using the Gromacs 'mdrun_mpi' module. We excluded the interactions between the peptide and system components other than α . The details of the PMF decomposition have been described in the Appendix of our recent work²⁴.

The final PMF and its standard error (uncertainty) were estimated by block averaging consecutive 100 ns time periods from the production run of each US window³⁷ (The first 100 ns data are not used). We ensured that the block size was significantly larger than the correlation time in each umbrella window.

3 Results and Discussion

3.1 Cholesterol Dependence: 0-30 mol % CHOL in PC or PS systems

Cholesterol is a small molecule composed of four rings with one hydroxyl group and one hydrocarbon chain, where the hydroxyl group is hydrophilic and the rest is hydrophobic. Cholesterol is an essential component of mammalian cell membranes, generally, present around 20 mol % in cells³⁸. Cholesterol facilitates cell signaling processes and assists in local lipid domain (raft) formation³⁹. It plays a major role in maintaining membrane structural integrity and fluidity of cell membranes⁴⁰⁻⁴⁶. The amphipathicity of cholesterol confers on it structural facility to align with phospholipids, and the planar and effective rigidity accommodate its ability to complementarily pack within the membrane, thus increasing bilayer order⁴⁷. Paradoxically, cholesterol increases the fluidity of membranes, as a result of its rapid flip-flop between the leaflets inside the bilayers^{48,49}.

3.1.1 Potentials of Mean Force (PMFs) of TAT Translocation in Systems of Varying Cholesterol (CHOL) Concentration Fig. 2 shows the PMFs of TAT translocation into PC or PS systems with different mole concentrations of cholesterol along the Rxn. Coord. ξ , which is the z distance between the center of mass




Fig. 2 PMF's of TAT translocation into model DPPC (left) and DPPS (right) lipid bilayers with different cholesterol (CHOL) percentage.

(c.o.m.) of the peptide and c.o.m. of the entire membrane. The peptide passes from bulk water ($\xi=6.0$ nm) to bilayer center ($\xi=0.0$ nm). The left panel shows the translocation free energies in zwitterionic DPPC membrane, and the right panel in anionic DPPS systems. In both zwitterionic and anionic lipid bilayers, the TAT peptide moves freely in the bulk water, where there is no free energetic difference as the Rxn. Coord. ξ ranges from 4.0 nm to 6.0 nm. However, at the membrane interface, the TAT peptide behaves differently in these two types of lipid systems. It does not strongly bind to the zwitterionic/neutral lipid bilayer interfaces, where no free energy minima are observed. In contrast, the TAT peptide strongly binds to the anionic lipids as indicated by a PMF minimum of -40 kJ/mol. This is in qualitative agreement with results of experiments^{13,16,17,50} and simulations^{51,52}. Similar lipid association preferences are observed for other CPPs such as nona-arginines^{19,20,53,54}. This favorable peptide binding in anionic lipid systems is mainly because of the strong electrostatic interactions between cationic TAT peptide with eight positive charges and the high density of negative charges of the membrane at the interface (see the charge density profiles of the DPPC and DPPS membrane systems in SI Fig. S1). We further notice that the molar concentration of cholesterol doesn't affect the depth of the free energy minimum at the interface of both zwitterionic and anionic lipid bilayers (see the results in Table 2), which implies that the enrichment of cholesterol in the membrane doesn't affect CPP association at a moderate cholesterol mole fraction. This can be understood by the fact that cholesterol molecules are mainly located inside the membrane near the hydrophobic core, and they almost have no effect on surface charge density (see the density profiles in SI Fig. S2), the latter because cholesterol is neutral, and because the electrostatic components of peptide-membrane interaction dominate over other dispersion and non-bonded

interaction forces.

Although, interface properties are not affected by the amount of cholesterol in the systems, the overall translocation free energy barrier increases as higher mole concentration of cholesterol is incorporated into membranes. Addition of cholesterol increases order of lipid tails (see the bond order parameter of DPPC, DPPS in SI Fig. S3), inducing more rigidity into our model membranes much like experimentally observed induction of the liquid-ordered (Lo) phase of membranes and increases elastic stiffness; increased stiffness works against peptide translocation by reducing membrane/bilayer deformability to form 'pore-like' configurations conducive for the peptide states in the center of the bilayer. Higher cholesterol fraction in the membrane impedes peptide translocation. Experiments show that cholesterol depletion facilitates peptide translocation⁵⁵. We note that the change in the curvature of the PMF's with increasing cholesterol content may be connected to an increasing elastic deformation penalty contribution described by a Helfrich-type model of membrane fluctuations. To first order, assuming equivalent global curvatures (extrinsic and Gaussian), differences in the steepness of the PMF curves may be related to some stiffness or rigidity property of the membranes we model. Connecting the angstrom-scale deformations we see in our simulations with curvature changes via Helfrich-type analysis may provide further insight into quantitative changes in membrane bending rigidities. This work continues as a further avenue of inquiry.

Furthermore, for the PC and PS systems with the same mole concentration of cholesterol, lower free energy barriers are observed in the PS systems. The free energy barrier is about 200-250 kJ/mol in PC membrane systems, and 115-235 kJ/mol in the PS membrane systems, respectively. There is 20 to 100 kJ/mol less free energy cost in the PS systems due to the favorable lipid-peptide interactions. Noteworthy is that most of the PMFs (except DPPS with 30% cholesterol) have a kink at around 0.5 nm of the Rxn. Coord. ξ . The PMFs flatten as the peptide moves toward the center of the bilayer from this kink position. As discussed in our recent work¹⁹, the flattened region corresponds to the formation of a transmembrane pore-like structure induced by the cationic peptide. Fig. 3 shows snapshots of the pore and defect structures in DPPC and DPPS systems with different cholesterol mole concentrations. The lack of a kink in the PMF of the DPPS membrane system mixed with 30 mol% cholesterol in Fig. 2 is due to the fact that no stable water pore was formed. This is shown clearly in Fig. 3. Once the pore is formed in the DPPS systems, the peptide can move through the pore with insignificant free energy

Table 2 Analysis of PMF's for TAT translocation across the PC or PS membranes with different mole fraction of cholesterol (PMF's in units of kJ/mol). The table includes the free energy barrier of peptide translocation from bulk to center (ΔG_{total}), the interfacial free energy minima relative to the bulk (ΔG_{min}) and the maximum free energy barrier from the free energy minimum to the center of the bilayer (ΔG_{max}).

Ratio ^a	ΔG_{total}	ΔG_{min}	ΔG_{max}	Error
0: 100: 0	198.5	-	198.5	1.0
10: 90: 0	205.6	-	205.6	1.1
20: 80: 0	228.9	-	228.9	0.5
30: 70: 0	255.1	-	255.1	1.2
0: 0: 100	115.3	-38.6	153.9	0.7
10: 0: 90	129.8	-39.1	168.9	1.0
20: 0: 80	141.8	-41.2	183.0	1.6
30: 0: 70	233.2	-41.4	274.6	1.3

^a: Ratio of CHOL:DPPC:DPPS

penalty. Table 2 summarizes the free energy barriers of different systems. The intrinsic pore formation free energy is highly correlated with membrane thickness as discussed in other work^{54,56}.

3.1.2 PMF Decomposition: Systems with Varying Cholesterol Composition To scrutinize the roles of cholesterol and other system components, we decompose the PMFs into the contributions of the components in the peptide-membrane systems, shown in Fig. 4. The sum of the component contributions matches the calculated PMF obtained from WHAM analysis (see Fig. S4 in SI). In both PC and PS systems, cholesterol contribution increases with increasing cholesterol mole percentage. However, the increments of the barrier in DPPS systems are slightly smaller than those in DPPC systems. Specifically, cholesterol components contribute to the barrier about 3 to 30 kJ/mol free energy in the DPPC systems, but only up to 25 kJ/mol in DPPS systems. Generally, increasing the concentration of cholesterol in the membrane disfavors peptide translocation. Nevertheless, compared to the total peptide translocation barrier, the contribution from cholesterol is very small, and the differences between PC and PS systems are negligible. Although cholesterol's contribution to the total PMFs is relatively small, it significantly affects stabilization of the TAT peptide inside the membrane. The small molecular size and relatively rapid diffusion of cholesterol in the interior of the bilayer allow it to easily associate with the peptide. Fig. 5 shows the amount of cholesterol around the TAT peptides in the first solvation shell (the width of the solvation shell was defined as 0.67 nm from all the beads of the peptide, and it has been chosen by the




Fig. 3 Snapshots of the center windows in 0-30 mol % cholesterol systems. Red, yellow, cyan and gray spheres represent the TAT peptide, water, phosphates and carbonyls, respectively. Cholesterol is shown in blue.

calculation of pair correlation functions between the peptide and water beads¹⁹). As more cholesterol molecules associate with the TAT peptides, and the number of negatively charged phosphates around the cationic peptide consequently decreases (see Fig. 6), peptide-lipid interactions are eventually weakened.

Fig. 7 shows the contribution to the PMFs from the lipids and all ions (including counter-ions of peptides and lipids) in the PC and PS lipid systems. These non-aqueous components confer thermodynamic stability for the peptide in the bilayer center in both PC and PS systems. However, this effect is reduced significantly as cholesterol molecules are added to the systems. With cholesterol at 30 mol %, overall stabilization is damped to zero in the DPPS systems, and becomes destabilizing in the DPPC systems.

In both PC and PS systems, the cholesterol and lipid-ion contribution stabilizes the peptide in the interface region. Minima are found in all cholesterol contributions. Cholesterols stabilize the peptide at the interface, and favor peptide association. However, this association reduces the stabilization from lipids, and results in roughly




Fig. 4 PMF decomposition showing cholesterol contributions to total PMF for TAT translocation into model DPPC (left) and DPPS (right) lipid bilayers with different CHOL percentages.




Fig. 5 Number of cholesterol molecules in shell surrounding TAT peptide




Fig. 6 Number of phosphates groups surrounding TAT peptide




Fig. 7 PMF decomposition showing sum of lipid (DPPC or DPPS) and ion (Na^+ and Cl^-) contributions to TAT translocation into model DPPC (left) and DPPS (right) lipid bilayers with different CHOL percentages.

no change of the peptide association in the membrane interface. At bilayer center, cholesterol increases the barrier of TAT translocation at high mole fractions, and contributes an overall destabilization effect. The weakened stabilization effect of lipids is attributable to replacement of stabilizing lipid groups in the peptide solvation shell.

3.2 Anionic Lipid Component Dependence: PC/PS systems with 0-20 mol % cholesterol

Certain experiments^{55,57} and simulations⁵⁸⁻⁶⁰ suggest that higher membrane cholesterol content reduces accumulation of the peptides in the membrane, and that CPPs prefer to penetrate via regions containing less cholesterol, these regions being supposedly of lower rigidity and more facile to deform possibly in order to accommodate peptide translocation. The above simulations of cholesterol dependence in neutral and anionic lipids recapitulate this observation; they further indicate that the cholesterol contribution solely relies on the mole concentration in the membrane composition, which is independent of the lipid charge states. Note that translocation barriers of

the TAT peptide are relatively lower in the anionic lipid systems. Experimental results show that in 20 mol % cholesterol and PC/PS mixed giant unilamellar vesicles (GUVs), rapid translocation of the TAT peptides was detected at 40 mol % DPPS composition. These experiments further suggest nanometer-size pores are involved via tracing fluorescent molecule leakage¹². To investigate the role of membrane surface charge in peptide internalization, we constructed a series of PC/PS mixed lipid bilayer systems with 20 mol % cholesterol varying the mole percentage of PS lipids from 0 mol % to the maximum 80 mol %. The corresponding cholesterol-free systems with the same ratio of PC:PS were also constructed.

We computed PMFs of the TAT peptides from the bulk water ($\xi=6.0$ nm) to the center of the bilayers ($\xi=0.0$ nm). Fig. 8 shows the PMFs of TAT translocation into CHOL/PC/PS membranes (left panel), and PC/PS mixed membranes (right panel) along the Rxn. Coord. ξ (the z distance between the c.o.m. of the peptide and the c.o.m of the membrane). The results are summarized in Table 3. The barrier from bulk to the center of the bilayer is significantly reduced by a factor




Fig. 8 PMFs of TAT translocation into model DPPC/DPPS mixed lipid bilayers with 20 mol % cholesterol (left panel), and 0 mol % cholesterol (right panel). The same PC:PS ratio is used in both systems, which is 4:0, 3:1, 2:2, 1:3, 0:4. The dashed arrow indicates the direction of increasing PS mole concentration.

of two with increasing mole percent of PS in the membrane. Specifically, by varying the ratio of PC:PS from 4:0 to 3:1, 2:2, 1:3 and 0:4, in the 20 mol % cholesterol systems, the free energy cost changes from around 230 kJ/mol to only 142 kJ/mol; in the cholesterol-free systems, the translocation barrier decreases even more to 115 kJ/mol. This trend agrees qualitatively with experimental observations^{55,57,61,62}. Unsurprisingly, in the cholesterol-depleted membrane systems, the free energy barrier is much lower.

Fig. 8 shows that the addition of PS into the PC bilayer gives rise to an interfacial free energy minimum and the depth of the minimum is further enhanced with increasing PS concentration. It indicates that although there is no strong association between the TAT peptide and neutral lipid bilayers, increasing the surface charges, such as adding anionic lipids into the membrane composition, can significantly enhance the peptide interfacial binding. Comparing the depth of the minima of the systems with the same PC:PS ratio in Table 3, we noticed that the 20 mol % and 0 mol % cholesterol mixture systems show almost quantitatively the same surface association and binding preference. It again implies that the interface properties are not affected by the amount of cholesterol in the systems, but rather the surface charges. Relating to a possible mechanistic rationale for the CPP translocation, strong peptide association will increase the local concentration of the peptide at the membrane surface. As a result, it may increase the number of translocation events with a relatively larger interfacial sample population, and further increase the translocation probability which manifests in observable internalization rates.

Table 3 The free energetic results of TAT PTD translocation across the PC/PS mixed membrane with 20 mol % cholesterol and no cholesterol (in units of kJ/mol). The table includes the free energy barrier of peptide translocation from bulk to center (ΔG_{total}), the interfacial free energy minima relative to the bulk (ΔG_{min}) and the maximum free energy barrier from the free energy minimum to the center of the bilayer (ΔG_{max}).

Ratio ^a	ΔG_{total}	ΔG_{min}	ΔG_{max}	Error
20: 80: 0	228.9	-	228.9	0.5
20: 60: 20	196.1	-15.0	211.1	1.5
20: 40: 40	172.1	-25.8	197.9	1.3
20: 20: 60	157.9	-34.5	192.4	1.4
20: 0: 80	141.8	-41.2	183.0	1.6
0: 100: 0	198.5	-	198.5	1.0
0: 75: 25	148.9	-14.3	163.2	1.6
0: 50: 50	131.7	-27.8	159.5	0.8
0: 25: 75	120.7	-34.0	154.7	0.9
0: 0: 100	115.3	-38.6	153.9	0.7

^a: Ratio of CHOL:DPPC:DPPS

3.2.1 Pore Formation and Water and Ion Flux

Our simulation results so far indicate (see Fig. 2 and Fig. 8) that despite large free energy barriers, there are structural factors that contribute in a stabilizing manner as a CPP translocates into the membrane center. This is particularly suggested by Fig. 2 showing the flattened regions of TAT translocation into bilayers of varying cholesterol concentration. This flattening of the PMF, as we^{19,20,54} and others^{37,63-67} have discussed in previous work, is intimately related to structural deformations of the bilayer-water configurations that accommodate transmembrane pore structures. From snapshots of the molecular dynamics simulations where the peptide is in the center of the bilayers (Fig. 9), we can see hydrophilic pores are induced in both 20 mol % cholesterol and cholesterol-depleted membrane systems. The membrane headgroups reorient to the rim of the channel, and the headgroup-peptide interactions stabilize the peptide inside the membrane. Water and ions solvated the peptide inside the pore, freely flowing through the pore and exchanging with the bulk solution. The kink positions of the PMFs in Fig. 8 show the maximum distance between the c.o.m. of the peptide and the c.o.m. of the membrane where the pore is readily generated and stable throughout the lifetime of the extended MD simulations we generate. The variation of the mole percentage of anionic lipids doesn't affect the kink positions in both types of systems.

The average pore configurations are further investigated by computing the density profiles of the membrane




Fig. 9 Snapshots of the center windows in DPPC/DPPS mixed membrane systems with 20 mol % cholesterol or no cholesterol. The same color coding is used as for Fig. 3.

508 along the lateral dimension. Fig. 10 and Fig. 11 show
 509 the densities of lipid head groups and tails. The pore⁵²³
 510 shape and channel size differ slightly upon changing PS⁵²⁴
 511 or cholesterol content. The lipids deform to a toroidal⁵²⁵
 512 shaped pore, and the head groups reside on the rim of⁵²⁶
 513 the pores. Furthermore, the narrow neck of the pore di-⁵²⁷
 514 ameter is around 1.5 to 2.0 nm, which coincides with an⁵²⁸
 515 experimental estimation of the pore size¹².⁵²⁹

516 **3.2.2 PMF Decomposition of TAT translocati-**⁵³¹
on in Different DPPS Concentration Systems⁵³²
 517 Apart from pore formation, anionic lipids play an impor-⁵³³
 518 tant role in the TAT peptide translocation. High mole⁵³⁴
 519 percentage of PS in the membrane composition signifi-⁵³⁵
 520 cantly reduces the free energetic barrier of the peptide⁵³⁶
 521 internalization. Cholesterol depletion further enhances⁵³⁷




Fig. 10 Two-dimensional density profiles $\rho(r, z)$ of (top panels) lipid head groups, and (bottom panels) tails for the TAT peptide penetrating into the center of the bilayer. All the profiles are computed from the 20 mol % cholesterol systems (A-E columns), and plotted as a function of the lateral radial distance with respect to the center of mass of the peptide (r) and the system z dimension. The number in the bracket of each column shows the CHOL:DPPC:DPPS ratio of the membrane composition.




Fig. 11 Two-dimensional density profiles $\rho(r, z)$ of (top panels) lipid head groups, and (bottom panels) tails for the TAT peptide penetrating into the the cholesterol depleted systems (A-E columns). The number in the bracket of each column shows the CHOL:DPPC:DPPS ratio of the membrane composition.

the trafficking of peptide across the membrane. Here,
 we again decompose the PMFs into the contributions of
 different components to investigate the associated free
 energetic dependencies. The sum of the component con-
 tributions is validated with the calculated PMF obtained
 from WHAM analysis (see Fig. S5 in SI).

Strong force-field based electrostatic interaction be-
 tween ions and peptide help maintain the peptide sol-
 vation and stabilize the peptide in the aqueous water
 solution. However, when the peptide moves from the
 hydrophilic environment to the hydrophobic core of the
 membrane, the decrease in local salt concentration in-
 curs large free energy penalty. The penalty is around
 250 kJ/mol in the DPPC bilayers with 20 mol % or no
 cholesterol systems, as shown in Fig. 12 (see the black




Fig. 12 Total PMF contribution from DPPS and ions (Na^+ and Cl^-) in 20% CHOL and no CHOL mixture systems. (note: water and DPPC contributions are not included in each curve.)




Fig. 13 Total number of phosphates in the first solvation shell of DPPC and DPPS in various PC:PS ratio systems. Black bars represent the 20 mol % cholesterol systems, and red bars represents cholesterol-free systems. The filled portions of the bars represent contribution from the phosphates from DPPC, and the unfilled are from the phosphates of DPPS.

solid curves with no symbols). This is also qualitatively consistent with the salt effect in the internalization of nonaarginine, which is another CPP molecule we studied previously¹⁹. Similar to the ions, another large destabilization penalty comes from water desolvation (shown in SI Fig. S6). After mixing DPPC with the DPPS membranes, the contributions of the ions together with the DPPS start to decrease. The strong stabilization effect from DPPS compensates the desalting effect and gives roughly an overall 100 kJ/mol stabilization free energy in 20 mol % cholesterol systems, and around 150 kJ/mol in the cholesterol-free systems after replacing all the DPPC lipids with DPPS. This agrees with previous simulation results in that both DPPC and DPPS are stabilizing CPP translocation. The stabilization mainly comes from the strong charge interactions between DPPS and the TAT peptides carrying 8 positive charges. In Fig. 13, we can see the coordination number of the negatively charged phosphates from DPPS in the first solvation shell of the TAT peptide continuously increases along with the mole percentage growth of DPPS, whereas the number of phosphates from DPPC coordinating to the peptide is gradually reduced.

Fig. 14 shows the total contribution from the membrane and ions containing DPPC, DPPS, Na^+ and Cl^- ions. The favorable interactions from DPPS reduce the barriers and contribute an overall stabilization effect. This can be attributed to the large amount of net negative surface charges in the anionic PS lipid systems compared to neutral PC lipids. However, in the systems containing cholesterol, the slightly weaker stabilization effect is due to the cholesterol binding to the peptides and reducing the density of lipids around the peptides. The cholesterol itself contributes a relatively small amount (4-12 kJ/mol) of destabilization effect (see Fig. S7 in SI). Furthermore, adding cholesterol to the membrane increases the order

of both DPPC and DPPS lipid molecules. Fig. 15 shows the average orientational bond order parameter P_2 of the lipid tail bonds, which is calculated from the average second-rank Legendre polynomial, $\langle \frac{1}{2}(3\cos^2\theta - 1) \rangle$ (θ is the angle between the direction of the bond and the bilayer normal). The values of P_2 represent the lipid bond alignment, where $P_2 = 1.0$ corresponds to perfect alignment with the bilayer normal and $P_2 = 0.0$ corresponds to a random orientation. Since the membrane deformation and pore formation caused by the peptide translocation disrupt membrane order, the higher order of lipid structures in cholesterol systems reduces the sta-




Fig. 14 Total PMF contribution from the system components: DPPS, ions (Na^+ and Cl^-) and DPPC in 20% CHOL and no CHOL mixture systems. (note: water contributions are not included in each curve.)




Fig. 15 Average bond order parameter

bilizing contribution from lipids.

Overall, the lipid stabilization effect reduces the translocation barrier of the peptide in the systems, but it is still insufficient to compensate the large free energetic penalty from the combined loss of water, ions and cholesterol interactions.

3.2.3 Peptide Mobility We address peptide permeability in this section. Dynamic permeability, or $\log(P_{dynamic})$, which is measured for small molecules, is an often-used experimental observable related to thermodynamic translocation free energy barriers accessible via MD simulations. In practice, procedures such as high-throughput, parallel artificial membrane permeability assays (PAMPA) and cell-based CaCo-2 assays are exploited to measure the dynamic permeability of small molecules. Of course, such methods cannot provide detailed atomistic insights about translocation. Presently, we apply the inhomogeneous solubility-diffusion model⁶⁸⁻⁷⁰ to estimate TAT dynamic permeabilities using the PMF's and local diffusivity profiles obtained from our MD simulations via the following expression:

$$\frac{1}{P_{dynamic}} = \int_{z_1}^{z_2} \frac{\exp[\beta W(z)]}{D(z)} dz \quad (3)$$

where $W(z)$ is the potential of mean force, $D(z)$ is the local diffusivity coefficient, and β is $\frac{1}{k_B T}$.

We used the protocol proposed by Hummer et. al^{71,72} to calculate the position-dependent diffusion coefficient, $D(z)$ along the membrane normal. Accordingly, the local diffusion coefficient of a single peptide from umbrella sampling MD simulations can be estimated by

$$D = \text{var}(z)/\tau \quad (4)$$

where the relaxation time, τ is obtained by the following equation

$$\tau \approx \left[\frac{n \text{var}(\bar{z})}{\text{var}(z)} - 1 \right] \Delta t / 2 \quad (5)$$

where, n is the number of data points in each umbrella sampling trajectory, $\text{var}(z)$ and $\text{var}(\bar{z})$ are the variance of z and variance of average z coordinate, respectively, and Δt is time interval between data points.

Unsurprisingly, peptide diffusion is greater in the neutral lipid systems than the anionic mixed systems in the interfacial region (see Fig. 16). This suggests that increasing surface charge in the PS-containing systems weakly changes the mobility of the peptide at the interface. In fact, this is qualitatively consistent with the experimental result. The CLSM images of a single TAT peptide on the GUV surfaces shows that the mobility of TAT on the neutral GUV surfaces is higher than on anionic GUVs; however increasing surface charge has very little impact on TAT mobility on the anionic GUV surface¹². The rate measured experimentally ($\sim 5 \times 10^{-6} \text{nm}^2 \cdot \text{ps}^{-1}$) is roughly 10 times slower than the result calculated from our simulations. Since the peptide is bound to a large fluorescence tracer in the experiments, the tracer may slow peptide diffusion on the membrane surface. Furthermore, the experiments were carried out at room temperature, instead of 350 K we used in simulation.

Table 4 and Table 5 show values of computed dynamic permeabilities, $P_{dynamic}$, and $\log(P_{dynamic})$ values for zero and twenty percent cholesterol systems with varying PS composition. Consistent with our computed PMF's, the permeabilities are essentially vanishingly small. This is in stark contrast to experimental observations of peptide permeation on the timescales of seconds to minutes^{12,73,74}. Though the absolute values of the permeabilities are inaccurate, the general trends follow the PMF profiles. Increasing PS composition of the simulated model membranes decreases barriers and subsequently increases permeabilities; systematically, permeabilities are greater in the cholesterol-free systems relative to the 20 percent cholesterol systems. This is explained through arguments of increased membrane rigidity induced by cholesterol as discussed in earlier sections.

4 Summary

In this work, we have studied the translocation thermodynamics of a cationic TAT peptide across cholesterol-

Table 4 Computed Dynamic Permeabilities from Inhomogeneous Diffusion-Solubility Model. Cholesterol-Free Systems with Varying PS Concentration

Percent PS	$P_{dynamic} (\frac{cm}{sec})$	$\log(P_{dynamic})$
0.0	7.1×10^{-30}	-67.12
25.0	1.4×10^{-22}	-50.3
50.0	8.6×10^{-20}	-43.9
75.0	4.8×10^{-18}	-39.9
100.0	3.8×10^{-17}	-37.8

Table 5 Computed Dynamic Permeabilities from Inhomogeneous Diffusion-Solubility Model. 20 Percent Cholesterol Systems with Varying PS Concentration

Percent PS	$P_{dynamic} (\frac{cm}{sec})$	$\log(P_{dynamic})$
0.0	5.3×10^{-35}	-78.9
20.0	3.0×10^{-30}	-68.0
40.0	3.3×10^{-26}	-58.7
60.0	6.0×10^{-24}	-53.5
80.0	4.1×10^{-22}	-49.3

659 containing and cholesterol-depleted DPPC/DPPS mem-695
 660 brane systems. We estimated the potentials of mean force-696
 661 by using umbrella sampling molecular dynamics simula-697
 662 tions coupled to Martini coarse-grained force field. In ac-698
 663 cordance with experimental observations, we consider the-699
 664 diffusive process of the peptide along a pre-defined Rxn-700
 665 Coord. ξ describing the z distance between the c.o.m of-701
 666 the peptide and the c.o.m of the membrane. Two ma-702
 667 jor effects, the cholesterol dependence and anionic lipid-703
 668 (or membrane surface charges) dependence, are carefully-704
 669 investigated. 705

670 First, by varying the content of cholesterol in DPPC-706
 671 or DPPS lipid bilayers, we observed a systematic change-707
 672 in the translocation PMFs. The addition of cholesterol-708
 673 into membrane increases the barriers of peptide translo-709
 674 cation across the membrane. However, the decomposi-710
 675 tion of the PMFs reveals that cholesterol contributes a-711
 676 weakly destabilizing effect. Further examining the con-712
 677 tribution from ions and lipids suggests that the coordi-713
 678 nation of cholesterol to the peptide replaces some of the-714
 679 lipid binding in the first solvation shell leading to signif-715
 680 icant decrease of the peptide-lipid interaction. Choles-716
 681 terol increases the alignment of the lipid bonds to the bi-717
 682 layer normal, which results in a higher order of the lipid-718
 683 molecules. The lipid-ordered phase impedes the reorien-719
 684 tation of the lipid molecules. The relatively stiff bonds-720
 685 of the lipid hinders the hydrophilic transmembrane pore-721
 686 formation where lipid reorientation is required. Thus, a-722




Fig. 16 Local diffusivity profiles for (a) 20% CHOL. in model DPPC/DPPS lipid bilayers with different percentage of DPPS. (b) NO CHOL. in model DPPC/DPPS lipid bilayers with different percentage of DPPS

large barrier is created in the cholesterol systems. The depletion of cholesterol reduces the translocation cost of the peptide, and favors formation of transmembrane pores. This is in agreement with experimental observations. Comparing the DPPC with DPPS type membrane, our results suggest that the more efficient permeation will occur in the anionic bilayer systems at the same mole percentage of cholesterol or no cholesterol. When there is no cholesterol, the free energy barrier reaches the smallest value in the DPPS-only system. The PMFs also reveal that the change of cholesterol level has a negligible effect on the peptide association to both DPPC and DPPS membranes.

We then systematically changed the mole percentage of anionic lipid DPPS in the presence and absence of cholesterol. The addition of anionic lipids to the neutral bilayer leads to emergence and further enhancement of an interfacially stable state. This is understood by the strong electrostatic interactions between the oppositely charged peptide and lipids. The barrier increases rapidly as peptide moves into the hydrophobic core of the membrane. Decomposition of the PMFs indicates a large penalty from desalting and desolvation of the charged peptide. The reduction of the translocation barrier is directly attributed to the mole percentage increase of DPPS. The preference of the peptide-anionic lipid interaction enhances the stabilization of the whole membrane. As shown in experiments, 40 mol % PS membrane enables rapid internalization of the TAT peptide into GUVs through a transmembrane pore. The PMFs illustrate that once the pore is formed, the peptide translocation proceeds with little free energetic cost. Additionally, we found that the hydrophilic pore size is on the nanometer scale and within the range of experimental estimates. The relative mobility of the peptide on the different membrane surfaces is qualitatively consistent with the CLSM

723 experiments.

770

724 Though we do not claim quantitative agreement with
 725 experimental measurements using the coarse-grained
 726 force fields described in this study, particularly with re-
 727 gard to permeability values, we emphasize that relative
 728 behaviors are captured by the models we use. The coarse-
 729 grained (CG) model we use overcomes the time and
 730 length scale limitations of all-atom simulations of large
 731 biomolecular systems at the cost of reducing the atomic
 732 details. More atomic information and accurate energetics
 733 may be gained by carrying out expensive full atomistic
 734 simulations. We suggest that systematic modifications of
 735 the CG force field can lead to further improvements to-
 736 wards more quantitative agreement between the current
 737 models and experiments, with the most critical property
 738 related to the barriers observed for translocation. Inco-
 739 porating experimental data on translocation kinetics into
 740 the model development is one alternative modification.
 741 Furthermore, reevaluation of the degeneracies associated
 742 with the types of reaction coordinates used in this study
 743 will need to be addressed in the future as well.

744 In sum, the present results evaluate the cholesterol and
 745 anionic lipid effect on peptide translocation, and qualita-
 746 tively recapitulate the transmembrane pore size and pep-
 747 tide mobility. We emphasize the significant reduction of
 748 the barrier heights in the presence of anionic lipid and
 749 absence of cholesterol. These findings complement the
 750 intricate studies of cell-penetrating peptides permeating
 751 through model membrane mixtures and provide complex
 752 picture of the interplay of various species. Recently, neg-
 753 atively charged lipids such as PS lipid are found accumu-
 754 lated at the tumor cell membrane surface, due to the over-
 755 expression of certain glycosaminoglycans^{75–79}. CPPs can
 756 be potentially used to selectively target the tumor cells
 757 and thus used for cancer diagnosis or delivery of oncologic
 758 therapies.

759 5 Acknowledgment

760 The authors acknowledge support from the National Sci-
 761 ence Foundation (CAREER:MCB:1149802). This pub-
 762 lication was made possible by computational resources
 763 through the Delaware COBRE program, supported by
 764 grants from the National Institute of General Medical
 765 Sciences - NIGMS (1 P30 GM110758-02) and (5 P30
 766 GM103519-05) in the Departments of Chemistry and Bio-
 767 chemistry and Chemical Engineering at the University of
 768 Delaware. S.P. thanks Nikunj Patel for past fruitful dis-
 769 cussion and encouragement.

- 1 A. D. Frankel and C. Pabo, *Cell*, 1988, **55**, 1189–1193.
- 2 M. Green and P. M. Loewenstein, *Cell*, 1988, **55**, 1179–1188.
- 3 I. L. Medintz, T. Pons, J. B. Delehanty, K. Susumu, F. M. Brunel, P. E. Dawson and H. Mattoussi, *Bioconjugate chemistry*, 2008, **19**, 1785–1795.
- 4 B. R. Liu, Y.-w. Huang, J. G. Winiarz, H.-J. Chiang and H.-J. Lee, *Biomaterials*, 2011, **32**, 3520–3537.
- 5 A. Eguchi, T. Akuta, H. Okuyama, T. Senda, H. Yokoi, H. Inokuchi, S. Fujita, T. Hayakawa, K. Takeda, M. Hasegawa *et al.*, *Journal of Biological Chemistry*, 2001, **276**, 26204–26210.
- 6 S. Veldhoen, S. D. Laufer, A. Trampe and T. Restle, *Nucleic acids research*, 2006, **34**, 6561–6573.
- 7 Y. Jiang, M. Li, Z. Zhang, T. Gong and X. Sun, *Current pharmaceutical biotechnology*, 2014, **15**, 256–266.
- 8 H. M. T. Hitsuda, M. Kitamatsu, A. Fujimura, F. Wang, T. Yamamoto, X. Han, H. Tazawa, A. Uneda, I. Ohmori, T. Nishiki, K. Tomizawa and H. Matsui, *Biomaterials*, 2012, **33**, 4665–4672.
- 9 R. R. Patlolla, P. R. Desai, K. Belay and M. S. Singh, *Biomaterials*, 2010, **31**, 5598–5607.
- 10 Y.-L. Tseng, J.-J. Liu and R.-L. Hong, *Molecular pharmacology*, 2002, **62**, 864–872.
- 11 I. D. Alves, C. Bechara, A. Walrant, Y. Zaltsman, C.-Y. Jiao and S. Sagan, *PLoS One*, 2011, **6**, e24096.
- 12 C. Ciobanasu, J. P. Siebrasse and U. Kubitscheck, *Biophys. J.*, 2010, **99**, 153–162.
- 13 Y. Su, A. J. Waring, P. Ruchala and M. Hong, *Biochemistry*, 2010, **49**, 6009–6020.
- 14 C.-Y. Jiao, D. Delaroche, F. Burlina, I. D. Alves, G. Chassaing and S. Sagan, *J. Biol. Chem.*, 2009, **284**, 33957–33965.
- 15 A. Walrant, L. Matheron, S. Cribier, S. Chaignepain, M.-L. Jobin, S. Sagan and I. D. Alves, *Anal. Biochem.*, 2013, **438**, 1–10.
- 16 X. Chen, F. Sa'adedin, B. Deme, P. Rao and J. Bradshaw, *Biochim. Biophys. Acta*, 2013, **1828**, 1982–1988.
- 17 Y. Rao, S. J. Kwok, J. Lombardi, N. J. Turro and K. B. Eisenthal, *Proc. Nat. Aca. Sci.*, 2014, **111**, 12684–12688.
- 18 A. Mishra, G. H. Lai, N. W. Schmidt, V. Z. Sun, A. R. Rodriguez, R. Tong, L. Tang, J. Cheng, T. J. Deming, D. T. Kamei *et al.*, *Proc. Nat. Aca. Sci.*, 2011, **108**, 16883–16888.
- 22 S. J. Marrink and D. P. Tieleman, *Chem. Soc. Rev.*, 2013, **42**, 6801–6822.
- 19 Y. Hu, X. Liu, S. K. Sinha and S. Patel, *J. Phys. Chem. B*, 2014, **118**, 2670–2682.
- 20 Y. Hu and S. Patel, *J. Membr. Biol.*, 2014, 1–11.
- 21 Z. Li, H. Ding and Y. Ma, *Soft Matter*, 2013, **9**, 1281–1286.
- 23 S. J. Marrink, A. H. D. Vries and A. E. Mark, *J. Phys. Chem. B*, 2004, **108**, 750–760.
- 24 Y. Hu, S. K. Sinha and S. Patel, *J. Phys. Chem. B*, 2014, **118**, 11973–11992.
- 25 Y. Hu, S. Ou and S. Patel, *J. Phys. Chem. B*, 2013, **117**, 11641–11653.
- 26 A. J. Rzepiela, D. Sengupta, N. Goga and S. J. Marrink, *Faraday discussions*, 2010, **144**, 431–443.
- 27 H. Lee and R. G. Larson, *J. Phys. Chem. B*, 2006, **110**, 18204–18211.
- 28 S. J. Marrink, H. J. Risselada, S. Yefimov, D. P. Tieleman and A. H. de Vries, *J. Phys. Chem. B*, 2007, **111**, 7812–7824.
- 29 L. Monticelli, S. K. Kandasamy, X. Periole, R. G. Larson, D. P. Tieleman, and S.-J. Marrink, *J. Chem. Theory Comput.*, 2008,

- 831 4, 819–834. 893
- 832 30 M. Seo, S. Rauscher, R. Pomès and D. P. Tieleman, *J. Chem. Theory Comput.*, 2012, **8**, 1774–1785. 894
- 833 31 D. H. de Jong, X. Periole and S. J. Marrink, *J. Chem. Theory Comput.*, 2012, **8**, 1003–1014. 895
- 834 32 G. Singh and D. P. Tieleman, *J. Chem. Theory Comput.*, 2011, **7**, 2316–2324. 896
- 835 33 J. L. Cascales, S. O. Costa, A. Garro and R. Enriz, *RSC Advances*, 2012, **2**, 11743–11750. 897
- 836 34 B. Hess, H. Bekker, H. J.C. Berendsen and J. G.E.M. Fraaije, *J. Comp. Chem.*, 1997, **18**, 1463–1472. 898
- 837 35 S. Kumar, J. M. Rosenberg, D. Bouzida, R. H. Swendsen and P. A. Kollman, *J. Comp. Chem.*, 1992, **13**, 1011–1021. 899
- 838 36 W. Humphrey, A. Dalke and K. Schulten, *Journal of Molecular Graphics*, 1996, **14**, 33–38. 900
- 839 37 K. Huang and A. E. García, *Biophys. J.*, 2013, **104**, 412–420. 901
- 840 38 D. Scherfeld, N. Kahya and P. Schwille, *Biophys. J.*, 2003, **85**, 3758–3768. 902
- 841 39 J. P. Incardona and S. Eaton, *Current opinion in cell biology*, 2000, **12**, 193–203. 903
- 842 40 R. Demel, K. Bruckdorfer and L. Van Deenen, *Biochimica et Biophysica Acta (BBA)-Biomembranes*, 1972, **255**, 321–330. 904
- 843 41 S. Raffy and J. Teissie, *Biophysical journal*, 1999, **76**, 2072–2080. 905
- 844 42 R. A. Demel and B. De Kruffy, *Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes*, 1976, **457**, 109–132. 906
- 845 43 G. W. Stockton and I. C. Smith, *Chemistry and physics of lipids*, 1976, **17**, 251–263. 907
- 846 44 P. Brûlet and H. M. McConnell, *Proc. Nat. Aca. Sci.*, 1976, **73**, 2977–2981. 908
- 847 45 R. A. Cooper, *Journal of supramolecular structure*, 1978, **8**, 413–430. 909
- 848 46 X. Xu and E. London, *Biochemistry*, 2000, **39**, 843–849. 910
- 849 47 H. Ohvo-Rekilä, B. Ramstedt, P. Leppimäki and J. Peter Slotte, *Progress in lipid research*, 2002, **41**, 66–97. 911
- 850 48 W. D. Bennett, J. L. MacCallum, M. J. Hinner, S. J. Marrink and D. P. Tieleman, *J. Am. Chem. Soc.*, 2009, **131**, 12714–12720. 912
- 851 49 J. A. Hamilton, *Current opinion in lipidology*, 2003, **14**, 263–271. 913
- 852 50 P. Wadhvani, R. Epand, N. Heidenreich, J. Bürck, A. Ulrich and R. Epand, *Biophys. J.*, 2012, **103**, 265–274. 914
- 853 51 M. Di Pisa, G. Chassaing and J.-M. Swiecicki, *Biochemistry*, 2014, ASAP. 915
- 854 52 H. D. Herce and A. E. Garcia, *Proc. Nat. Aca. Sci.*, 2007, **104**, 20805–20810. 916
- 855 53 J. R. Marks, J. Placone, K. Hristova and W. C. Wimley, *J. Am. Chem. Soc.*, 2011, **133**, 8995–9004. 917
- 856 54 Y. Hu, S. K. Sinha and S. Patel, *Langmuir*, 2015, ASAP. 918
- 857 55 P. Saalik, A. Niinep, J. Pae, M. Hansen, D. Lubenets, U. Langel and M. Pooga, *J. Control. Release*, 2011, **153**, 117–125. 919
- 858 56 W. Bennett, N. Sapay and D. P. Tieleman, *Biophys. J.*, 2014, **106**, 210–219. 920
- 859 57 J. Pae, P. Säälilik, L. Liivamägi, D. Lubenets, P. Arukuusk, Ü. Langel and M. Pooga, *Journal of Controlled Release*, 2014, **192**, 103–113. 921
- 860 58 W. D. Bennett, J. L. MacCallum and D. P. Tieleman, *J. Am. Chem. Soc.*, 2009, **131**, 1972–1978. 922
- 861 59 T. J. Yacoub, A. S. Reddy and I. Szleifer, *Biophys. J.*, 2011, **101**, 378–385. 923
- 862 60 C. L. Wennberg, D. van der Spoel and J. S. Hub, *J. Am. Chem. Soc.*, 2012, **134**, 5351–5361. 924
- 863 61 K. Simons and W. L. Vaz, *Annu. Rev. Biophys. Biomol. Struct.*, 2004, **33**, 269–295. 925
- 864 62 F. Frézar and A. Garnier-Suillerot, *Biochim. Biophys. Acta*, 1998, **1389**, 13–22. 926
- 865 63 S. Yesylevskyy, S.-J. Marrink and A. E. Mark, *Biophys. J.*, 2009, **97**, 40–49. 927
- 866 64 H. Lee and R. G. Larson, *J. Phys. Chem. B*, 2008, **112**, 7778–7784. 928
- 867 65 W. D. Bennett and D. P. Tieleman, *J. Chem. Theory Comput.*, 2011, **7**, 2981–2988. 929
- 868 66 D. Sun, J. Forsman, M. Lund and C. E. Woodward, *Phys. Chem. Chem. Phys.*, 2014, **16**, 20785–20795. 930
- 869 67 W. F. Drew Bennett and D. Peter Tieleman, *Acc. Chem. Res.*, 2014, **47**, 2244–2251. 931
- 870 68 J. M. Diamond and Y. Katz, *J. Membr. Biol.*, 1974, **17**, 121–154. 932
- 871 69 S.-J. Marrink and H. J. C. Berendsen, *J. Phys. Chem.*, 1994, **98**, 4155–4168. 933
- 872 70 C. T. Lee, J. Comer, C. Herndon, N. Leung, A. Pavlova, R. V. Swift, C. Tung, C. N. Rowley, R. E. Amaro, C. Chipot, Y. Wang and J. C. Gumbart, *J. Chem. Inf. Model.*, 2016, **56**, 721–733. 934
- 873 71 G. Hummer, *New J. Phys.*, 2005, **7**, 34. 935
- 874 72 F. Zhu and G. Hummer, *J. Chem. Theory Comput.*, 2012, **8**, 3759–3768. 936
- 875 73 F. Duchardt, M. Fotin-Mleczek, H. Schwarz, R. Fischer and R. Brock, *Traffic*, 2007, **8**, 848–866. 937
- 876 74 G. Tunnemann, G. Ter-Avetisyan, R. M. Martin, M. Stockl, A. Herrmann and M. C. Cardoso, *J. Biol. Chem.*, 2009, **14**, 469–476. 938
- 877 75 M.-L. Jobin and I. D. Alves, *Biochimie*, 2014, **107**, 154–159. 939
- 878 76 K. Matsuda, H. Maruyama, F. Guo, J. Kleeff, J. Itakura, Y. Matsumoto, A. D. Lander and M. Korc, *Cancer research*, 2001, **61**, 5562–5569. 940
- 879 77 J.-h. Lee, H. Park, H. Chung, S. Choi, Y. Kim, H. Yoo, T.-Y. Kim, H.-J. Hann, I. Seong, J. Kim *et al.*, *Journal of Biological Chemistry*, 2009, **284**, 27167–27175. 941
- 880 78 R. D. Sanderson, *Seminars in cell & developmental biology*, 2001, pp. 89–98. 942
- 881 79 I. Vlodyavsky, O. Goldshmidt, E. Zcharia, R. Atzmon, Z. Rangini-Guatta, M. Elkin, T. Peretz and Y. Friedmann, *Seminars in cancer biology*, 2002, pp. 121–129. 943




Fig. 17 table of content